271 results on '"Kieseier, B. C."'
Search Results
2. Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID)
3. Neuromuskuläre Störungen beim Intensivpatienten
4. Toxic effector molecules in the pathogenesis of immune-mediated disorders of the central nervous system
5. Monomethylfumarate reduces in vitro migration of mononuclear cells
6. Multiple sclerosis - a dynamic field with a need for excellent education
7. Neuromuskuläre Erkrankungen bei Intensivpatienten
8. Peripheral blood levels of matrix metalloproteinase-9 predict lesion volume in acute stroke
9. Bacteria and their cell wall components uniformly co-activate interleukin-17-producing thymocytes
10. Immunogenicity with peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis: 2-year data from the randomised phase 3, multicentre ADVANCE study in relapsing-remitting multiple sclerosis: EP4152
11. Clinical efficacy and safety of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis: 2-year data from the pivotal phase 3 ADVANCE study: OS4204
12. The CSF JCV antibody index for diagnosis of natalizumab-associated PML: OS2124
13. Treatment of active secondary progressive multiple sclerosis with treosulfan
14. Plasmaaustausch als Therapieoption bei neurologischen Erkrankungen
15. Multiple Sklerose – Revision der neuen McDonald-Diagnosekriterien
16. Blockade von Adhäsionsmolekülen mit Natalizumab in der Therapie der Multiplen Sklerose: Aktueller Studienstand
17. Akute disseminierte Enzephalomyelitis: Pathogenese, Diagnose, Behandlung und Prognose
18. Statine zur Behandlung von Erkrankungen des zentralen Nervensystems: Eine Standortbestimmung aus Forschung und Klinik
19. Multiple Sklerose: potenzielle Therapieansätze und Update laufender Studien
20. Jean-Martin Charcot im Spiegel der deutschen Nervenheilkunde
21. Mitoxantron zur Therapie der Multiplen Sklerose
22. Cholesterinsenker—eine neue Therapieoption bei Multipler Sklerose?: Statine als Immunmodulatoren
23. Chronisch inflammatorische demyelinisierende Polyneuropathie
24. T cell activation status determines the cytokine pattern induced by zymosan and bacterial DNA both in thymocytes and splenocytes
25. Changes to the adaptive immunity in blood and CSF during the long-term therapy with natalizumab: SC344
26. Matrix-Metalloproteinasen Mögliche Ansatzpunkte neuer Therapien bei entzündlich demyelinisierenden Erkrankungen des Nervensystems: Mögliche Ansatzpunkte neuer Therapien bei entzündlich demyelinisierenden Erkrankungen des Nervensystems
27. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis
28. Central nervous system involvement in patients with monoclonal gammopathy and polyneuropathy
29. Bioavailability of Interferon-beta in patients with multiple sclerosis - fishing for the surrogate
30. Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab: Evidence for disease heterogeneity
31. Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis
32. Second IVIg course in Guillain-Barré syndrome with poor prognosis. The non-randomised ISID study
33. The monocyte-macrophage system is affected in lysosomal storage diseases: an immunoelectron microscopic study
34. Current treatment practice of Guillain-Barré syndrome
35. ANTI-GD1A ANTIBODIES IMPAIR NEURITE OUTGROWTH IN AN IN VITRO MODEL OF NERVE REGENERATION
36. TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME IS EXPRESSED IN THE INFLAMED PERIPHERAL NERVOUS SYSTEM
37. INTERLEUKIN-23 IN ACUTE INFLAMMATORY DEMYELINATION OF THE PERIPHERAL NERVOUS SYSTEM
38. Current treatment practice of Guillain-Barré syndrome
39. Optical coherence tomography measures axonal loss in multiple sclerosis independently of optic neuritis
40. Treosulfan impedes the migration of immunocompetent cells
41. A patient with a benign course of neuromyelitis optica (Devic’s syndrome) over 12 years: MRI follow up and histological findings
42. No evidence of increased oxidative degradation of urate to allantoin in the CSF and serum of patients with multiple sclerosis
43. Exome Array GWAS in 10,000 Germans Identifies Association between MUC22 and Multiple Sclerosis
44. Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects
45. Individualized patient counseling can improve adherence by efficient management of avoidable adverse events
46. Conversion from clinically isolated syndrome to multiple sclerosis:A large multicentre study
47. Blockade von Adhäsionsmolekülen mit Natalizumab in der Therapie der Multiplen Sklerose. Aktueller Studienstand
48. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis
49. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis
50. The CSF JCV antibody index for diagnosis of natalizumab-associated PML
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.